Separate data for patients with aggressive tumour subtype (as defined by a Gleason score greater than 7, presence of distant metastasis, a prostate-specific antigen level greater than 100 ng/ml or death from prostate cancer) were available from all six GWASs (cases, n = 4450; controls, n = 12,724). This evidence concerns the gene KLK3 and neoplasm.